Directly observed treatment for tuberculosis (multiple letters) [1]

Lancet

Volumn 353, Issue 9147, 1999, Pages 145-148

  Uplekar, M ^a   Walley, J ^a   Newell, J ^a   Leinhardt, C ^a   Rowley, J ^a   Manneh, K ^a   Frieden, T R ^a   Harries, A D ^a   Salaniponi, F M ^a   Kwanjana, J H ^a   Kochi, A ^a   Zwarenstein, M ^a  

^a Nuffield Health   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

DRUG SELF ADMINISTRATION; HEALTH CARE COST; HUMAN; LETTER; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS CONTROL; COST BENEFIT ANALYSIS; DEVELOPING COUNTRY; ECONOMICS; LUNG TUBERCULOSIS; NOTE; SOUTH AFRICA; TREATMENT REFUSAL;

ANTITUBERCULAR AGENTS; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; HUMANS; SELF ADMINISTRATION; SOUTH AFRICA; TREATMENT REFUSAL; TUBERCULOSIS, PULMONARY;

EID: 0033537222     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)00009-9     Document Type: Letter

References (5)

1. M Zwarenstein JH Schoeman C Vundule CJ Lombard M Tatley Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis Lancet 352 1998 1340 1343
2. L Suryanarayana K Vembu R Rajalakshmi C Satayanarayana Status of short course chemotherapy under National Tuberculosis Programme Ind J Tubercul 41 1994 211 216
3. P Garner What makes DOT work? Lancet 352 1998 1326 1327
4. Mukund Uplekar Sheela Rangan Alternative approaches to improve treatment adherence in tuberculosis control programme Ind J Tubercul 42 1995 67 74
5. K Jochem RJ Fryatt I Harper H White H Luitel R Dahal Tuberculosis control in remote districts of Nepal comparing patient-responsible short-course chemotherapy with long-course treatment Int J Tubercul Lung Dis i 1997 502 508